Joanne Imperial, serving as a director at CapsoVision, Inc. (CV), reported the disposition of 1,200 shares of the company's common stock on June 8, 2026. The transaction was executed at a per-share price of $7.1555, resulting in total proceeds of $8,586. Following the sale, Imperial holds a direct position of 1,687 shares in CapsoVision.
The sale was documented through a Form 4/A filing, which serves as an amendment to an earlier disclosure. The amendment explicitly noted that the report was submitted after the required deadline because the company was not immediately notified of the reportable securities sale within the mandated timeframe.
CapsoVision's shares are currently trading at $7.37. This price point marks a 31% decline year-to-date, contrasting with a 110% gain recorded over the past twelve months. Independent valuation analysis from InvestingPro indicates that CapsoVision appears overvalued at current levels, placing the company on its list of Most Overvalued stocks. The analysis suggests that deeper insights into CV's financial health and valuation metrics are available through additional InvestingPro Tips.
The insider transaction follows CapsoVision's first-quarter 2026 financial results, which missed analyst expectations. The company reported an actual earnings per share (EPS) of -$0.15, falling short of the forecasted -$0.11. This discrepancy resulted in a negative surprise of 36.36%. Despite the earnings miss, investor sentiment remained optimistic. Benchmark reaffirmed its Speculative Buy rating on CapsoVision stock, setting a price target of $10. The firm highlighted ongoing product development programs as a key driver.
CapsoVision is advancing several regulatory submissions. The company is on track for mid-year 510(k) clearance for an AI-assisted reading feature for CapsoCam Plus. Additionally, plans are in place for a 510(k) submission for CapsoCam Colon in the third quarter of 2026. A clinical study for CapsoCam UGI in pancreatic cancer detection is scheduled to begin this month.
In corporate governance updates, CapsoVision shareholders recently re-elected three Class I directors and ratified the appointment of its independent auditor at the annual meeting. The re-elected directors will serve until the 2029 annual meeting of stockholders.